Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study)

Massimiliano Fabbiani, Simona Di Giambenedetto, Manuela Colafigli et al.|Scandinavian Journal of Infectious Diseases|2013

Cited by 29